CW June 2006
Volume 15Issue Number 6 June 2006 ISSN 10593802 Low-Dose Thalidomide Effective and Safe for Relapsed or Refractory Multiple MyelomaGiving thalidomide at one-quarter the usual dose may be just as effective and result in fewer side effects for patients with relapsed multiple myeloma, according to a new report at the American Society of Clinical Oncology Annual Meeting.
Go to Previous Page Go to Next Page Source & Additional Reading Report at the American Society of Clinical Oncology Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
